Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Upifitamab Rilsodotin (XMT-1536) as Post-Platinum Maintenance Therapy for Participants With Recurrent, Platinum-Sensitive, Ovarian Cancer (UP-NEXT)

NCT05329545 is registered in ClinicalTrials.gov with Mersana Therapeutics as lead sponsor.

NCT NCT05329545
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05329545 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Upifitamab Rilsodotin (XMT-1536) as Post-Platinum Maintenance Therapy for Participants With Recurrent, Platinum-Sensitive, Ovarian Cancer (UP-NEXT)
Lead sponsor
Mersana Therapeutics
Phase
Phase 3
Overall status
Terminated
Start date
June 23, 2022
Completion date
September 29, 2023
Enrollment
20 (actual)
Sites
30

Conditions

As the registry lists them; a condition with its own page is linked.

fallopian tube cancer, high grade serous ovarian cancer, primary peritoneal cancer